Abstract
Background COVID-19 is a new disease that is associated with high morbidity that has spread around the world. Credible estimating is crucial for control and prevention. Nowadays, hybrid models have become popular, and these models have been widely implemented. Better estimation accuracy may be attained using time-series models. Thus, our aim is to forecast the number of COVID-19 cases with time-series models.
Objective Using time-series models to predict deaths due to COVID-19.
Design SARIMA, NNAR, and SARIMA-NNAR hybrid time series models were used using the COVID-19 information of the Republic of Turkey Health Ministry.
Participants We analyzed data on COVID-19 in Turkey from March 11, 2020 to February 22, 2021.
Main Measures Daily numbers of COVID-19 confirmed cases and deaths.
Materials and methods We fitted a seasonal autoregressive integrated moving average (SARIMA)–neural network nonlinear autoregressive (NNAR) hybrid model with COVID-19 monthly cases from March 11, 2020, to February 22, 2021, in Turkey. Additionally, a SARIMA model, an NNAR model, and a SARIMA–NNAR hybrid model were established for comparison and estimation.
Results The RMSE, MAE, and MAPE values of the NNAR model were obtained the lowest in the training set and the validation set. Thus, the NNAR model demonstrates excellent performance whether in fitting or forecasting compared with other models.
Conclusions The NNAR model that fits this study is the most suitable for estimating the number of deaths due to COVID-19. Hence, it will facilitate the prevention and control of COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04678193
Funding Statement
no
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Republic of Turkey Health Ministry, COVID-19 Information Page, https://covid19.saglik.gov.tr
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Republic of Turkey Health Ministry, COVID-19 Information Page, https://covid19.saglik.gov.tr
